DARPins: Targeted Protein Therapeutics Beyond Antibodies
DARPins form a novel and unique class of protein therapeutics. They combine the desired properties of antibody therapeutics with many of the beneficial characteristics of small molecules: DARPins have superior potencies, are robust, low-cost in their development, safe and can penetrate tissue easily. This new class of molecules opens the door for transforming new drug formats.
Molecular Partners established a robust platform to discover and develop DARPin-based medicines. Drug candidates targeting indications in ophthalmology, inflammation and oncology are being developed by Molecular Partners, with a lead DARPin which has completed Phase I/IIa clinical trials. Further candidates are under development in strategic partnerships with renowned biopharmaceutical companies.
Molecular Partners fully owns the DARPin technology. We are highly dedicated to exploiting the immense potential of the DARPin technology to address unmet medical needs or to drastically improve existing therapies.